Cell sorting dilution reagent, kit, application of cell sorting dilution reagent and cell sorting method
By using serum albumin and antioxidants in cell sorting diluents, the problems of cell aggregation and platelet aggregation in frozen umbilical cord blood are solved, the sorting efficiency and purity of CD34+ cells are improved, and the risk of animal protein residue is reduced, thus achieving the realization of Efficient cell sorting.
Patent Information
- Application Number
- CN202411165809.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-23
- Publication Date
- 2024-11-08
AI Technical Summary
There are cell aggregation and platelet aggregation problems during cell sorting in frozen umbilical cord blood, resulting in low cell sorting recovery, poor purity and low viability. There are safety risks for bovine serum albumin and anticoagulants in existing dilutions. And anticoagulants may weaken the effect of all-purpose nucleases and affect the sorting effect.
Using cell sorting and dilution reagents containing serum albumin and antioxidants, antioxidants include acetylcysteine and nicotinamide, which replaces traditional anticoagulants and is used to freeze the sorting of CD34+ cells in umbilical cord blood to improve cell protection. and sorting efficiency.
By adding antioxidants, cell aggregation is reduced, cell sorting is improved, cell sorting is improved, protection of frozen umbilical cord blood cells is enhanced, and CD34-cells are efficiently acquired, thus reducing the cost of animal protein residue detection, and improving sorting effect.
Smart Images

Figure CN118909941A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biotechnology, and in particular to a cell sorting dilution reagent, a kit and application thereof, and a cell sorting method. Background Art
[0002] The following statements merely provide background information related to the present disclosure and do not necessarily constitute prior art.
[0003] CD34 is a currently recognized surface marker of human hematopoietic stem / progenitor cells. Umbilical cord blood contains about 1% of CD34-positive cells (hereinafter referred to as CD34+ cells). Umbilical cord blood has the characteristics of wide source, low immunogenicity and easy storage, which makes it more convenient in clinical application. Therefore, isolating CD34+ cells from umbilical cord blood is a very critical step in the research and application of hematopoietic stem / progenitor cells.
[0004] Cryopreserved cord blood is the main method for storing cord blood hematopoietic stem cells. All cord blood hematopoietic stem cell products currently on the market are cryopreserved cord blood. The first approved expanded cord blood hematopoietic stem cell product (OMISIRGE, Gamida Cell) is also derived from cryopreserved cord blood. Immunomagnetic bead sorting is currently the main method for isolating CD34+ cells from cord blood for subsequent applications, including direct immunomagnetic bead sorting from cord blood and immunomagnetic bead sorting after obtaining mononuclear cells through density gradient centrifugation.
[0005] Since 1995, there has been a classic resuscitation scheme for frozen cord blood. Most research and products using frozen cord blood as materials follow this scheme (Rubinstein et al.) for cord blood resuscitation. During the sorting process of frozen cord blood, due to the inevitable damage to cells caused by cryopreservation and resuscitation, cells are prone to agglutination and formation of cell clumps during the sorting process. One of the main reasons is the rupture of granulocytes, which releases sticky genetic material inside the cells, causing cell agglomeration; the other is the cell agglomeration caused by platelet aggregation. Both are the main reasons for low cell sorting recovery rate, poor purity, and low cell viability.
[0006] At present, the pretreatment link based on cryopreserved cord blood sorting is to remove the DMSO component in the cryopreserved solution by dilution and centrifugation, and then resuspend the cells and sort the process by commercial sorting diluent. At present, the conventional method is to use PBS or DPBS as a solvent, add BSA to protect the cells, add anticoagulants (EDTA or sodium citrate), form chelates with calcium ions, prevent blood coagulation, and play an antiplatelet aggregation role at the same time, and eliminate the contents such as DNA released by the rupture of white blood cells (mainly granulocytes) by DNAse I, reducing cell adhesion. Commonly used sorting diluents such as the sorting diluent of Miltenyi Biotec of Germany.
[0007] However, conventional commercial diluents are mostly bovine serum albumin (BSA), which poses a potential safety risk to product applications and is one of the ingredients that should be avoided in biotherapy products. Accordingly, the presence of BSA makes the cost of animal protein residue detection in products higher. At the same time, anticoagulants slow platelet aggregation by complexing calcium ions, but anticoagulants can also complex magnesium ions, which may weaken or render the omnipotent nuclease ineffective, and even cause the two to a certain extent to aggravate the formation of cell clumps, resulting in unstable sorting results.
[0008] There is a big difference in the activity of frozen umbilical cord blood compared with fresh umbilical cord blood. In the process of separating CD34+ cells, multiple key process links will affect the number, vitality and function of the separated cells. Therefore, exploring an efficient method for separating CD34+ cells from frozen umbilical cord blood is crucial to improving the application value of frozen umbilical cord blood and its subsequent research and application effects.
[0009] In view of this, the present invention is proposed. Summary of the invention
[0010] The object of the present invention is to provide a cell sorting dilution reagent and a cell sorting method using the cell sorting dilution reagent, so as to alleviate the defects of the cell sorting reagents and methods in the prior art.
[0011] In order to solve the above technical problems, the present invention particularly adopts the following technical solutions:
[0012] In a first aspect, a cell sorting dilution reagent is provided, which contains serum albumin and an antioxidant, wherein the antioxidant includes acetylcysteine and / or nicotinamide.
[0013] In a second aspect, a cell sorting kit is also provided, which comprises the cell sorting dilution reagent of the first aspect.
[0014] In a third aspect, there is also provided the use of the cell sorting dilution reagent of the first aspect or the cell sorting kit of the second aspect in cell sorting.
[0015] In a fourth aspect, a cell sorting method is also provided, which comprises sorting target cells from cells dispersed in a diluent, wherein the diluent contains the cell sorting dilution reagent of the first aspect.
[0016] Compared with the prior art, the present invention has the following beneficial effects:
[0017] The cell sorting dilution reagent provided by the present invention comprises serum albumin and an antioxidant, wherein the antioxidant comprises acetylcysteine and / or nicotinamide. The antioxidant selected by the present invention has a CDE record, has extensive application experience in clinical practice, has extremely low side effects, and has the advantages of safety, easy access, and economical price. The cell sorting dilution reagent provided by the present invention can better protect the cell state by adding an antioxidant instead of an anticoagulant, thereby reducing cell aggregation while increasing the protective effect on cells, and improving separation efficiency and cell sorting effect. The cell sorting dilution reagent is used to sort CD34+ cells from frozen umbilical cord blood, and can stably and efficiently obtain CD34+ cells and CD34- cells, thereby achieving efficient use of umbilical cord blood resources. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the following briefly introduces the drawings required for use in the specific implementation methods or the description of the prior art. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0019] Figure 1 The cell viability and cell recovery rate of CD34- cells and CD34+ cells after sorting in Effect Example 1, where "split red blood cells" refers to the red blood cell lysing group, and "non-split red blood cells" refers to the group without red blood cell lysis;
[0020] Figure 2 The cell purity of CD34+ cells after sorting in Effect Example 1, where "split erythrocytes" means the group with lysed erythrocytes, and "non-split erythrocytes" means the group without lysed erythrocytes;
[0021] Figure 3 The cell viability and cell recovery rate of the CD34- cells after cryopreservation and recovery after sorting in Effect Example 1, where "split red blood cells" refers to the red blood cell lysing group, and "non-split red blood cells" refers to the group without red blood cell lysis;
[0022] Figure 4 The cell viability and cell recovery rate of different experimental groups in effect example 2;
[0023] Figure 5 The cell viability and cell recovery rate of CD34+ cells and CD34- cells in different experimental groups of the repeated experiment in Effect Example 2;
[0024] Figure 6 The cell viability and cell recovery rate corresponding to the sorting dilution solution with different NAC concentrations in Effect Example 3;
[0025] Figure 7The cell viability and cell recovery rate corresponding to the sorting dilution solution with different NAM concentrations in effect example 3;
[0026] Figure 8 The cell viability and cell recovery rate corresponding to the sorting diluent containing NAC or NAM in Effect Example 3;
[0027] Fig. 9 The cell viability and cell recovery rate corresponding to the sorting diluent containing NAC and PBS as the solvent in Effect Example 3;
[0028] Fig.10 The results of multiple repetitions of sorting the same portion of umbilical cord blood using the sorting diluents of Example 2 and Comparative Example 1 in Effect Example 3 include cell viability and cell recovery rate. DETAILED DESCRIPTION
[0029] The technical solution of the present invention will be clearly and completely described below in conjunction with the embodiments. Obviously, the described embodiments are part of the embodiments of the present invention, rather than all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0030] In a first aspect, a cell sorting dilution reagent is provided, wherein the cell sorting dilution reagent contains serum albumin and an antioxidant, wherein the antioxidant includes acetylcysteine and / or nicotinamide.
[0031] Acetylcysteine, also known as N-acetyl-L-cysteine (NAC), has a chemical formula of C5H9NO3S. It is a commonly used antioxidant and is widely used in cell, animal and clinical research. NAC is also a mucolytic agent. The principle is that the sulfhydryl group in NAC can break the disulfide bonds in the mucin polypeptide chain in the mucus, thereby decomposing the mucin. Because it has anti-inflammatory and mucus-dissolving effects, it is clinically used to treat a variety of respiratory diseases accompanied by a large amount of mucus. In an optional embodiment, the working concentration of acetylcysteine is 0.1 to 2 mM, for example, it can be but not limited to 0.1, 0.5, 1, 1.5 or 2 mM, preferably 1 mM.
[0032] Nicotinamide (NAM) is an amide compound of nicotinic acid and a water-soluble B vitamin. It has anti-inflammatory and antioxidant effects, is an important component of coenzyme I and coenzyme II, and plays an important role in maintaining the normal physiological functions of tissue cells. In an optional embodiment, the working concentration of nicotinamide is 2.5 to 10 mM, for example, but not limited to 2.5, 3, 4, 5, 6, 7, 8, 9 or 10 mM.
[0033] In an optional embodiment, the working concentration of serum albumin is 0.5-5% w / v, for example, but not limited to 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5 or 5% w / v.
[0034] In an alternative embodiment, the serum albumin comprises bovine serum albumin (BSA) or human serum albumin (HSA).
[0035] In an optional embodiment, the cell sorting dilution reagent is used for the target cells applied to the human body after sorting, and the serum albumin is human serum albumin, which avoids the cost of BSA removal and detection, reduces the risk of clinical application, and is closer to clinical application needs. And the experimental results show that using 5% w / v HSA instead of 0.5% w / v BSA enhances the protective effect of cryopreserved umbilical cord blood cells and improves the cell recovery rate.
[0036] In an optional embodiment, the cell sorting dilution reagent further contains dextran 40.
[0037] In an optional embodiment, the working concentration of the dextran 40 is 1-2.5% w / v, for example, but not limited to 1, 1.5, 2 or 2.5% w / v.
[0038] In an optional embodiment, the solvent of the cell sorting dilution reagent is PBS (Phosphate-Buffered Saline), DPBS (Dulbecco's Phosphate-Buffered Saline) or normal saline (NS).
[0039] In an optional embodiment, the cell sorting dilution reagent contains human serum albumin, an antioxidant, dextran 40 and normal saline. The normal saline containing dextran 40 is a solvent for clinical use, and there is a medicinal commercial reagent. In terms of separation effect, it has a better protective effect on the separated target cells than ordinary buffer. And human serum albumin, dextran 40 and normal saline are all medicinal reagents or pharmaceutical excipients, which can be safely used in clinical practice. Therefore, the components of the cell sorting dilution reagent in this embodiment are all medicinal materials or GMP grade reagents, which achieves a better sorting result than conventional commodity sorting reagents, and is more conducive to cost control, supports the conversion of enlarged volume process, and has good clinical application value.
[0040] In an optional embodiment, the antioxidant is acetylcysteine, and the cell sorting dilution reagent uses physiological saline as a solvent and contains 0.5-5% w / v human serum albumin, 1-2.5% w / v dextran 40 and 0.1-2 mM acetylcysteine.
[0041] In an optional embodiment, the cell sorting dilution reagent uses physiological saline as a solvent and contains 5% w / v human serum albumin, 1% w / v dextran 40 and 1 mM acetylcysteine.
[0042] In an optional embodiment, the antioxidant is nicotinamide, and the cell sorting dilution reagent uses physiological saline as a solvent and contains 0.5-5% w / v human serum albumin, 1-2.5% w / v dextran 40, and 2.5-10 mM nicotinamide.
[0043] In a second aspect, a cell sorting kit is also provided, which comprises the cell sorting dilution reagent of the first aspect.
[0044] In an optional embodiment, the cell sorting kit further comprises a resuscitation dilution reagent, wherein the resuscitation dilution reagent comprises serum albumin and dextran 40.
[0045] In an optional embodiment, the resuscitation dilution reagent includes 0.1% w / v human serum albumin and 1% w / v dextran 40, with physiological saline as the solvent.
[0046] In an optional embodiment, the kit further comprises one or more of an antibody, a solid phase carrier, a nuclease and an erythrocyte lysate, wherein the antibody specifically binds to the target cell, for example, specifically binds to a surface molecule of the target cell.
[0047] In an optional embodiment, the solid phase carrier includes but is not limited to one or more of a magnetic separation column and a magnetic separation rack that does not require column separation.
[0048] In alternative embodiments, the antibody specifically binds to CD34 or CD3.
[0049] In an alternative embodiment, the nuclease comprises a universal nuclease.
[0050] In a third aspect, there is also provided the use of the cell sorting dilution reagent of the first aspect or the cell sorting kit of the second aspect in cell sorting.
[0051] In an alternative embodiment, the use comprises isolating target cells from a blood sample.
[0052] In an optional embodiment, the blood sample includes a frozen blood sample.
[0053] In an optional embodiment, the use comprises isolating target cells from umbilical cord blood.
[0054] In an optional embodiment, the target cells include CD34+ cells (CD34 positive cells), CD34- cells (CD34 negative cells) or CD3+ cells (CD3 positive cells).
[0055] In an optional embodiment, the target cells include human hematopoietic stem / progenitor cells.
[0056] In a fourth aspect, a cell sorting method is provided, which comprises sorting target cells from cells dispersed in a diluent, wherein the diluent contains the cell sorting dilution reagent of the first aspect. The cell sorting method is for non-diagnosis and treatment purposes.
[0057] In an optional embodiment, the diluent is the cell sorting dilution reagent of the first aspect.
[0058] In an optional embodiment, the sorting of target cells includes separating the target cells using a solid phase carrier connected to an antibody.
[0059] In an optional embodiment, the antibody specifically binds to a surface molecule of the target cell.
[0060] In an optional embodiment, the solid phase carrier includes but is not limited to one or more of a magnetic separation column and a magnetic separation rack that does not require column separation.
[0061] In an optional embodiment, the cell sorting includes sorting target cells from a blood sample.
[0062] In an optional embodiment, the blood sample includes a frozen blood sample.
[0063] In an optional embodiment, the blood sample comprises umbilical cord blood.
[0064] In an optional embodiment, the cell sorting method includes sorting target cells from frozen umbilical cord blood.
[0065] In an optional embodiment, the umbilical cord blood is concentrated with hydroxyethyl starch before sorting.
[0066] In an optional embodiment, the frozen umbilical cord blood is concentrated with hydroxyethyl starch before freezing.
[0067] Hydroxyethyl starch concentration can remove most of the red blood cells. Although the total blood volume is reduced, the red blood cell concentration in cryopreserved cord blood is still high. Although density gradient centrifugation can remove more than 90% of red blood cells, it will inevitably lose too much CD34- and also cause the loss of some CD34+ cells. In order to obtain more CD34+ cells and CD34- cells, it is preferred to separate cells directly from umbilical cord blood concentrated with hydroxyethyl starch.
[0068] In an optional embodiment, the sorting method also includes lysing red blood cells before sorting. Lysing red blood cells before sorting reduces the volume of cell sedimentation. When using magnetic beads coupled with antibodies to sort the target cells, the volume of magnetic bead incubation can be reduced, the amount of antibodies used for sorting magnetic beads can be reduced, the cost of antibody application in the sorting process can be effectively controlled, and the cell recovery rate can be effectively increased. In addition, the problem of reduced cell recovery rate and purity due to excessive red blood cells and coagulation in the sorting process can be effectively avoided. This solution can improve the purity of CD34+ cells when used to sort CD34+ cells, while ensuring that the CD34- cell components have better cryopreservation resuscitation rate and recovery rate, ensuring the subsequent research or product application of CD34- cells.
[0069] In an optional embodiment, the separation method further comprises treating the cells with a nuclease before lysing the red blood cells. After the cryopreserved umbilical cord blood is resuscitated, broken cells will be present in the blood, releasing nucleic acids and proteins, causing cell agglutination. Therefore, in the process of separating target cells from cryopreserved umbilical cord blood, a nuclease is used to degrade nucleic acids in the system.
[0070] In an optional embodiment, the nuclease includes a universal nuclease, which requires the presence of magnesium ions to function. The traditional anticoagulant ethylenediaminetetraacetic acid (EDTA) is an important metal ion chelator that can complex calcium ions. EDTA potassium salt is commonly used as a blood anticoagulant. 2+ , preventing blood from clotting. EDTA can also complex magnesium ions, which may cause the effects of both omnipotent nuclease and EDTA to fail, and even have the risk of aggravating cell coagulation, which will also lead to unstable sorting results. In the cell sorting method provided by the present invention, a cell sorting dilution reagent in which EDTA is replaced by an antioxidant is used for sorting, thereby avoiding the above problems.
[0071] In an optional embodiment, the target cells include CD34+ cells, CD34- cells or CD3+ cells.
[0072] The present invention is further described below by means of specific examples. However, it should be understood that these examples are only used for more detailed description and should not be construed as limiting the present invention in any form.
[0073] The main reagents used in the following examples are:
[0074] Normal saline (NS), Fuzhou Neptuno Pharmaceutical Co., Ltd.; dextran 40 (DEX40), Xi'an Wanlong Pharmaceutical Co., Ltd.; human serum albumin (HSA), Jetbelin Biological Products Co., Ltd., Switzerland; MACS BSA Stock Solution, Miltenyi Biotec, Germany; BenzoNuclease, Suzhou Jinan Protein Technology Co., Ltd.; CD34 Nanobeads human, Nanjing GenScript Biotechnology Co., Ltd.; N-acetylcysteine (NAC), Beyotime Biotechnology Co., Ltd.; red blood cell lysate, either self-prepared or commercial reagents.
[0075] The preparation method of 20% DEX40 used in the following examples is as follows:
[0076] Preparation of 20% DEX40 (200 mL): Measure 40 g DEX40 powder and 1.8 g sodium chloride powder in a beaker, add about 140 mL of distilled water and stir with a glass rod to dissolve, then continue to add distilled water and use a volumetric flask to make up to 200 mL, filter through a 0.22 micron filter membrane, seal, and store at room temperature.
[0077] The preparation method of red blood cell lysis solution is as follows:
[0078] Accurately weigh 8.3g NH4Cl, 1g KHCO3, and 0.037g EDTA-Na2 and put them into a container. Add 100mL sterile water for injection and mix thoroughly to dissolve, then make up to 1000mL. Filter through a 0.22 micron filter membrane, seal, and store at 4 degrees for later use.
[0079] Example 1
[0080] This embodiment provides a sorting diluent, which contains 5% HSA and 0.1 mM NAC, and the solvent is physiological saline containing 1% DEX40, and is stored at 4 degrees for future use.
[0081] Example 2
[0082] This embodiment provides a sorting diluent, which contains 5% HSA and 1 mM NAC, and the solvent is physiological saline containing 1% DEX40, and is stored at 4 degrees for future use.
[0083] Example 3
[0084] This embodiment provides a sorting diluent, which contains 5% HSA and 2mM NAC, and the solvent is physiological saline containing 1% DEX40, and is stored at 4 degrees for future use.
[0085] Example 4
[0086] This embodiment provides a sorting diluent, which contains 5% HSA and 5mM NAC, and the solvent is physiological saline containing 1% DEX40, and is stored at 4 degrees for future use.
[0087] Example 5
[0088] This embodiment provides a sorting diluent, which contains 5% HSA and 2.5 mM NAM, and the solvent is physiological saline containing 1% DEX40, and is stored at 4 degrees for future use.
[0089] Example 6
[0090] This embodiment provides a sorting diluent, which contains 5% HSA and 10 mM NAM, and the solvent is physiological saline containing 1% DEX40, and is stored at 4 degrees for future use.
[0091] Example 7
[0092] This embodiment provides a sorting diluent, which contains 0.5% BSA and 1 mM NAC, and the solvent is PBS, and is stored at 4 degrees for future use.
[0093] Comparative Example 1
[0094] This comparative example provides a sorting diluent, which contains 0.5% BSA and 2mM EDTA, and the solvent is PBS, and is stored at 4 degrees for future use.
[0095] Comparative Example 2
[0096] This comparative example provides a sorting diluent, which contains 0.5% HSA and 2mM EDTA, and the solvent is PBS, and is stored at 4 degrees for future use.
[0097] Comparative Example 3
[0098] This comparative example provides a sorting diluent, which contains 2.5% HSA and 2mM EDTA, and the solvent is PBS, and is stored at 4 degrees for future use.
[0099] Comparative Example 4
[0100] This comparative example provides a sorting diluent, which contains 5% HSA and 2mM EDTA, and the solvent is PBS, and is stored at 4 degrees for future use.
[0101] Example 8
[0102] This embodiment provides a cell sorting method, including cord blood resuscitation, red blood cell lysis, magnetic bead incubation and magnetic bead sorting. The cord blood used in this embodiment is concentrated with hydroxyethyl starch before freezing.
[0103] (1) Umbilical cord blood resuscitation:
[0104] Preheat the water bath to 40°C in advance, take out the frozen umbilical cord blood from the liquid nitrogen tank, and take it out when it melts in the water bath to an "ice-water mixture" state.
[0105] Disinfect the blood bag with alcohol, place it in a biosafety cabinet, and transfer the umbilical cord blood to a 50mL centrifuge tube using a 50mL syringe. Measure the volume of the umbilical cord blood, take 10μL of the umbilical cord blood sample and dilute it 20 times with normal saline and count it. Count 2 to 3 times with a fluorescent cell analyzer and take the average. Reserve a small amount of blood sample for flow cytometry. The remaining umbilical cord blood samples are subsequently centrifuged and cell sorted.
[0106] Add an equal volume of pre-cooled resuscitation diluent to the cord blood, shake gently, and equilibrate at room temperature for 5 minutes. Add resuscitation diluent again to dilute 4 times (complete 8 times dilution in steps). Level the centrifuge bottle, centrifuge at 400g for 20 minutes at 4-8℃, speed 9, speed 3 to remove the cryopreservation solution. After centrifugation, aspirate and discard the supernatant. The volume of the precipitate should not exceed 5mL.
[0107] (2) Lysis of red blood cells:
[0108] Mix the cell pellet by gently shaking, add BenzoNuclease (final concentration 50U / mL) according to the total volume after lysing red blood cells, dilute at a ratio of 1:5000, and incubate at room temperature for 10 minutes. After incubation at room temperature, add 2 times the volume of red blood cell lysis solution. After red blood cell lysis is completed, add an equal volume of recovery diluent and dilute 1:1 to stop red blood cell lysis. Gently mix the cells and centrifuge them: 4℃, 400g, 10min, speed up 9, speed down 3. After centrifugation, aspirate and discard the supernatant, being careful not to disturb the cell pellet.
[0109] (3) Magnetic bead incubation:
[0110] Cell counting before incubation: After lysis and centrifugation, resuspend the cell pellet with sorting diluent. Take a small amount of cell suspension and dilute it 50-100 times with physiological saline (counting density range 1-3×10 5 / mL) for counting. Add an appropriate amount of sorting diluent according to the count and adjust the cell density to 1×10 8 / mL. After mixing the magnetic bead antibody (CD34 Nanobeads human), add an appropriate amount of magnetic beads to the cell suspension at a concentration of 100 μL magnetic beads per 1 mL of cell suspension, and incubate in a 4°C refrigerator for 30 min. After the incubation, add pre-cooled sorting diluent to each tube and adjust the cell concentration to 1×10 based on the count before incubation. 7 / mL, centrifugation conditions were 4-8°C, 300g, 10min, ascending speed 9, descending speed 3.
[0111] (4) Magnetic bead sorting:
[0112] After centrifugation, discard the supernatant and add an appropriate amount of pre-cooled sorting diluent to each tube to resuspend the precipitate according to the cell count results before incubation, so that the cell density is no higher than 1×10 8 / mL (ideal cell density 0.1~1×10 8 / mL). The sorting steps were performed according to the instructions of GenScript CD34+ cell sorting.
[0113] The sorted CD34+ cells and CD34- cells were centrifuged separately at 300 g for 10 min, with an increase speed of 9 and a decrease speed of 3.
[0114] After discarding the supernatant of CD34+ cells, resuspend them in no more than 1 mL of cell culture medium and measure the volume of the suspension. Count the cells with the original solution.
[0115] After discarding the supernatant of CD34- cells, add about 10 mL of saline to resuspend and measure the volume. Take a small amount of cell suspension and dilute it 20 times or 50 times with saline and count (the cell count concentration is 1-3×10 5 / mL).
[0116] (5) Cell detection: Flow cytometry was used to detect the proportion of CD34+ cells in CD34-positive cells and the proportion of CD3+ cells in CD34- cells.
[0117] The preparation method of the resuscitation diluent in this embodiment is as follows:
[0118] Preparation of resuscitation diluent (500 mL): 2.5 mL 20% HSA, 25 mL 20% DEX40, 472.5 mL NS, mix well and store at 4 degrees. The final concentration is a physiological saline solution containing 1% DEX40 and 0.1% HSA. After preparation, store at 4 degrees for use.
[0119] Example 9
[0120] This embodiment provides a cell sorting method, which differs from Embodiment 8 only in that red blood cells are not lysed before incubation with magnetic beads, that is, step (2) of Embodiment 8 is not included.
[0121] Effect Example 1
[0122] By pre-treating the umbilical cord blood samples to be sorted by lysing red blood cells, the sorting effect of frozen umbilical cord blood CD34+ cells can be effectively improved and stabilized:
[0123] Comparing the cell sorting methods provided in Example 8 and Example 9, the sorting diluents are both the sorting diluents used in Comparative Example 1.
[0124] The methods of isolating CD34+ cells from cryopreserved umbilical cord blood in Examples 8 and 9 are both based on a relatively high total white blood cell count (>1×108 The method is based on the actual clinical application needs. Although the umbilical cord blood used has been concentrated with hydroxyethyl starch to remove most of the red blood cells, the number of residual red blood cells is still more than 100 times that of white blood cells. Excessive residual red blood cells will aggravate cell adhesion during the separation process and reduce separation efficiency. By comparing the two methods of lysing red blood cells and not lysing red blood cells during the separation process, it was found that the viability, recovery rate and purity of CD34+ cells were significantly improved after lysing red blood cells, and the recovery rate of CD34- cells was also significantly improved ( Figure 1 and Figure 2 In addition, since CD34- cells are also commonly used and important product components in practical applications, this protocol continues to test the cryopreservation and resuscitation effects of the CD34- cells sorted in Examples 8 and 9 ( Figure 3 ). It was found that after CD34- cells were revived from cryopreservation, although the cell recovery rate of both treatment methods decreased, the cell recovery rate of the erythrocyte lysing group was significantly better than that of the non-erythrocyte lysing group, and the cell viability was higher ( Figure 3 ). In addition, the non-lysed red blood cells group is more likely to form cell clumps during the cryopreservation and resuscitation process, exacerbating cell loss or affecting the clinical application of the product.
[0125] Effect Example 2
[0126] Avoid the introduction of animal serum proteins, reduce product application risks, and reduce product residue detection costs:
[0127] Based on the consideration of BSA residual detection in the actual application of hematopoietic stem cell products, and the fact that frozen umbilical cord blood is slightly less active than fresh umbilical cord blood, in order to improve the protection effect on cells, this solution uses different concentrations of HSA to replace 0.5% BSA as a new sorting diluent in conventional commercial diluents. The sorting method is carried out according to the sorting method provided in Example 8. The groups are as follows:
[0128] Table 1 Experimental groups
[0129] Group 1 Comparative Example 1 PBS + 0.5% BSA + 2mM EDTA Group 2 Comparative Example 2 PBS+2mM EDTA+0.5%HSA Group 3 Comparative Example 3 PBS+2mM EDTA+2.5%HSA Group 4 Comparative Example 4 PBS+2mM EDTA+5%HSA
[0130] The results showed that in terms of cell viability, there was no significant difference between HSA and BSA at the same concentration (0.5%), and there was no significant difference between different HSA concentrations. In terms of CD34- cell viability, the HSA group performed better, and as the HSA concentration increased, the CD34- cell viability performance became better ( Figure 4 ).
[0131] In terms of cell recovery rate, HSA and BSA (0.5%) at the same concentration have comparable effects. As the concentration of HSA increases, the protective effect on cells increases, and the recovery rates of CD34+ cells, CD34- cells, and CD3+ cells show an upward trend. Overall, 5% HSA performs better ( Figure 4 ). The results of three repeated experiments (groups 1 and 4) verified that when the diluent solvent was PBS and the anticoagulant was 2mM EDTA, the group with 5% HSA added to the diluent had a better sorting effect than the group with 0.5% BSA, and the recovery rates of CD34+ cells and CD34- cells (including CD3+ cells) were higher. HSA can replace BSA with equivalent or better results ( Figure 5 ).
[0132] Effect Example 3
[0133] By adding antioxidants instead of anticoagulants to reduce cell aggregation, the effect of cryopreserved umbilical cord blood CD34+ cell sorting can be improved:
[0134] Under the same conditions of cord blood resuscitation and red blood cell lysis, the sorting effects of adding different concentrations of antioxidants to 1% Dex40-5% HSA-NS sorting diluent and commercial diluent (containing anticoagulant EDTA) were compared. The sorting method was carried out according to the sorting method provided in Example 8, and the sorting diluents used were the sorting diluents of Comparative Example 1 and Examples 1 to 7, respectively. The experimental groups were as follows:
[0135] Table 2
[0136] Group 1 Comparative Example 1 PBS + 0.5% BSA + 2mM EDTA Group 2 Example 1 NAC-100 μM+1% Dex40-5%HSA-NS Group 3 Example 2 NAC-1 mM + 1% Dex40-5% HSA-NS Group 4 Example 3 NAC-2 mM + 1% Dex40-5% HSA-NS Group 5 Example 4 NAC-5 mM + 1% Dex40-5% HSA-NS Group 6 Example 5 NAM-2.5 mM+1%Dex40-5%HSA-NS Group 7 Example 6 NAM-10 mM+1%Dex40-5%HSA-NS Group 8 Example 7 PBS + 0.5% BSA + 1mM NAC
[0137] The results showed that in terms of cell viability, the CD34+ cell viability of the sorting diluent containing NAC was equivalent to that of Comparative Example 1 when the NAC concentration was 100μM and 1mM, and the cell viability decreased significantly when the NAC concentration was 2mM; the CD34- cell viability was equivalent to that of Comparative Example 1 when the NAC concentration was 100μM, and was better than that of Comparative Example 1 when the NAC concentration was 1mM, and the CD34- cell viability decreased when the NAC concentration was 2mM. In terms of cell recovery rate, the NAC concentration was equivalent to that of Comparative Example 1 when it was 1mM.
[0138] Further comparison of the effects of different concentrations of NAC revealed that when the NAC concentration was greater than 2 mM, both cell viability and recovery rate decreased significantly ( Figure 6 ), indicating that the concentration of NAC should not be too high. In summary, the data show that the sorting diluent can replace EDTA in the commercial diluent by adding the antioxidant NAC, and it has obvious advantages in the separation effect of CD34- cells. The concentration range of NAC is between 100μM and 2mM, and 1mM has the best effect.
[0139] When NAM was used to replace the anticoagulant EDTA, it was found that the separation effect was also comparable to that of the original dilution solution, and the viability and recovery rate of CD34+ and CD34- cells were comparable to those of Comparative Example 1 ( Figure 7 ). However, in the comparison of the effects of NAC and NAM, in terms of cell viability, the CD34+ cell viability of the 1mM NAC group and the 10mM NAM group was comparable to that of the control group, and the CD34- cell viability was better than that of the control group 1; in terms of CD34+ cell recovery rate, the 10mM NAM group and the 1mM NAC group were comparable to that of the control group 1, but in terms of CD34- cell recovery rate, the 1mM NAC group was significantly better than the 10mM NAM group and the control group 1 ( Figure 8 ), indicating that not all antioxidants have the same effect, and NAC has a more obvious protective effect on cells. In summary, NAC can replace the anticoagulant EDTA in the sorting diluent, which significantly improves the separation and protection of CD34+ cells and CD34- cells.
[0140] The above experimental results show that the sorting diluent 1% Dex40-5% HSA-NS + antioxidant can reduce cell aggregation while having a better protective effect on cells. It can completely replace the anticoagulant EDTA, improve the sorting recovery rate of frozen umbilical cord blood CD34+ cells and CD34- cells, and improve the cell state obtained by sorting. Among them, the antioxidant NAC has a more prominent effect, with an effective concentration range of 100μM-2mM, and 1mM NAC has the best effect. In this scheme, the sorting diluent solvent is physiological saline, which is economical and easy to obtain, and is a pharmaceutical reagent, which is closer to clinical needs.
[0141] The main active ingredients in this sorting diluent are human serum albumin and antioxidants. The use of different solutions does not limit the sorting effect. The physiological saline in the sorting diluent can be replaced with PBS or DPBS solution to achieve the same effect. The data show that, as shown in Example 7 and Comparative Example 1, on the basis of PBS+0.5% BSA, after replacing EDTA with 1mM NAC, the viability and recovery rate of CD34+ cells and CD34- cells are also significantly improved ( Fig. 9 ).
[0142] In addition, inevitably, there are certain differences between different umbilical cord blood samples, which are mainly manifested in the different numbers of red blood cells, platelets, and the proportions of mononuclear cells and granulocytes in white blood cells. On the one hand, the aggregation of red blood cells and platelets will lead to cell aggregation and coagulation; on the other hand, granulocytes are more likely to rupture and release nucleic acids after cryopreservation and resuscitation than mononuclear cells, leading to cell clumping. Therefore, the cell sorting efficiency between different umbilical cord blood may fluctuate (such as the 40-80% recovery rate of CD34+ cells in different umbilical cord blood in this scheme). However, the use of different sorting diluents for the same umbilical cord blood can still reflect the advantages and stability of the sorting diluents in this scheme in terms of cell viability and cell sorting effect ( Fig.10 ), and the sorting efficiency is comparable to or better than that recorded in the literature or conventional reagents.
[0143] In summary, the sorting diluent in the above embodiment achieves an equivalent or even better sorting effect by adding an antioxidant to replace the use of an anticoagulant in a conventional cryopreserved umbilical cord blood sorting diluent. By adding an antioxidant widely used in clinical practice, the interference of conventional anticoagulants with universal nucleases or DNAse I in combination with magnesium ions in use is avoided, and the problem of cell agglomeration caused by the release of cell rupture contents and coagulation in cryopreserved umbilical cord blood can be better solved, effectively improving the sorting stability and effectiveness.
[0144] At the same time, the components of the sorting diluent in the above embodiment are all pharmaceutical excipients or GMP-grade reagents, which are suitable for clinical applications, and the raw materials are safe, easy to obtain, and economical, so that the product cost can be more effectively controlled. By avoiding the introduction of animal-derived components, the cost and complexity of related residue detection are reduced, which will be more conducive to product transformation and cost control.
[0145] The sorting process scheme in the above embodiment can be applied to the sorting of small volume or clinical grade umbilical cord blood, and can also be applied to the separation of other blood samples or cells except cryopreserved umbilical cord blood CD34+ cells.
[0146] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.
Claims
1. A cell sorting dilution reagent, characterized in that: Contains serum albumin and antioxidants, including acetylcysteine and / or nicotinamide.
2. The cell sorting dilution reagent according to claim 1, characterized in that: The working concentration of acetylcysteine is 0.1-2 mM, preferably 1 mM; Optionally, the working concentration of nicotinamide is 2.5-10 mM.
3. The cell sorting dilution reagent according to claim 1, characterized in that: The working concentration of the serum albumin is 0.5-5% w / v; Optionally, the serum albumin comprises bovine serum albumin or human serum albumin; Optionally, the cell sorting dilution reagent further contains dextran 40; Optionally, the working concentration of the dextran 40 is 1 to 2.5% w / v; Optionally, the solvent of the cell sorting dilution reagent is PBS, DPBS or physiological saline.
4. The cell sorting dilution reagent according to any one of claims 1 to 3, characterized in that: The cell sorting dilution reagent contains human serum albumin, antioxidant, dextran 40 and normal saline; The cell sorting dilution reagent uses physiological saline as a solvent and contains 0.5-5% w / v human serum albumin, 1-2.5% w / v dextran 40 and 0.1-2 mM acetylcysteine; Or, the cell sorting dilution reagent uses physiological saline as a solvent, contains 0.5-5% w / v human serum albumin, 1-2.5% w / v dextran 40, and 2.5-10 mM nicotinamide; Optionally, the cell sorting dilution reagent uses physiological saline as a solvent and contains 5% w / v human serum albumin, 1% w / v dextran 40 and 1 mM acetylcysteine.
5. A cell sorting kit, characterized in that: A cell sorting dilution reagent comprising the cell sorting dilution reagent according to any one of claims 1 to 4.
6. The kit according to claim 5, characterized in that Also included is a resuscitation dilution reagent, wherein the resuscitation dilution reagent includes serum albumin and dextran 40; Optionally, the resuscitation dilution reagent includes 0.1% w / v human serum albumin and 1% w / v dextran 40, with physiological saline as the solvent; Optionally, the kit further comprises one or more of an antibody, a solid phase carrier, a nuclease and a red blood cell lysate, wherein the antibody specifically binds to the target cell; Optionally, the antibody specifically binds to CD34 or CD3; Optionally, the nuclease comprises a universal nuclease.
7. Use of the cell sorting dilution reagent according to any one of claims 1 to 4, or the cell sorting kit according to claim 5 or 6 in cell sorting.
8. The use according to claim 7, characterized in that: The application includes isolating target cells in a blood sample; Optionally, the blood sample includes a frozen blood sample; Optionally, the use comprises isolating target cells from umbilical cord blood; Optionally, the target cells include CD34+ cells, CD34- cells or CD3+ cells; Optionally, the target cells include human hematopoietic stem / progenitor cells.
9. A cell sorting method, characterized in that: The method comprises sorting target cells from cells dispersed in a diluent, wherein the diluent contains the cell sorting diluent reagent according to any one of claims 1 to 4.
10. The cell sorting method according to claim 9, characterized in that: The sorting of target cells comprises separating the target cells using a solid phase carrier connected to an antibody, wherein the antibody specifically binds to the target cells; Optionally, the cell sorting includes sorting target cells from a blood sample; Optionally, the blood sample includes a frozen blood sample; Optionally, the blood sample comprises umbilical cord blood; Optionally, the umbilical cord blood is concentrated with hydroxyethyl starch before sorting; Optionally, the sorting method further comprises lysing red blood cells before sorting; Optionally, the sorting method further comprises treating the cells with a nuclease before lysing the red blood cells; Optionally, the nuclease comprises a universal nuclease; Optionally, the target cells include CD34+ cells, CD34- cells or CD3+ cells; Optionally, the target cells include human hematopoietic stem / progenitor cells.
Citation Information
Cited By
Target cell in-vitro sorting method for cell therapy
CN120098921A
